Hemogenyx Partners with Kure.ai for Ultrafast CAR-T Manufacturing

Dec 19, 2024•7 months ago

Contract Type

partnership

BiotechnologyHealth Care

Description

Hemogenyx has announced a partnership with Kure.ai to advance ultrafast CAR-T manufacturing. The collaboration aims to accelerate the development and production of CAR-T cell therapies for the treatment of blood and autoimmune diseases.

Company Information

Company

Hemogenyx

About

Hemogenyx is a biotechnology company specializing in the research and development of novel therapies to treat blood and autoimmune diseases.

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Hemogenyx Partners with Kure.ai for Ultrafast CAR-T Manufacturing

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Agreement Insights

Company Information